〔1〕Metzger M J，et al．Horizontal transmission of clonal cancer cells causes leukemia in soft-shell clams〔J〕．Cell，2015，161（2）：255-263.
〔2〕Zhou C．Lung cancer molecular epidemiology in China：recent trends〔J〕．Transl Lung Cancer Res．2014，3（5）：270-279.
〔3〕Yock T I，et al．Quality of life outcomes in proton and photon treated pediatric brain tumor survivors〔J〕．Radiother Oncol，2014，113（1）：89-94.
〔4〕Yadav M，et al．Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing〔J〕．Nature，2014，515（7528）：572-576.
〔5〕Warren G W，et al．The 2014 Surgeon General's report：「The health consequences of smoking — 50 years of progress」：a paradigm shift in cancer care〔J〕．Cancer，2014，120（13）：1914-1916.
〔6〕Solomon B J，et al．First-line crizotinib versus chemotherapy in ALK-positive lung cancer〔J〕．N Engl J Med，2014，371（23）：2167-2177.
〔7〕Snyder A，et al．Genetic basis for clinical response to CTLA-4 blockade in melanoma〔J〕．N Engl J Med，2014，371（23）：2189-2199.
〔8〕Shi Y，et al．A prospective，molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology （PIONEER） 〔J〕．J Thorac Oncol，2014，9（2）：154-162.
〔9〕Shen L，Ji H F．Ceritinib in ALK-rearranged non-small-cell lung cancer〔J〕．N Engl J Med，2014，370（26）：2537.
〔10〕Shaw A T，Engelman J A．Ceritinib in ALK-rearranged non-small-cell lung cancer〔J〕．N Engl J Med，2014，370（26）：2537-2539.
〔11〕Sayin V I，et al．Antioxidants accelerate lung cancer progression in mice〔J〕．Sci Transl Med，2014，6（221）：221ra15.
〔12〕Mitin T A，Zietman L．Promise and pitfalls of heavy-particle therapy〔J〕．J Clin Oncol，2014，32（26）：2855-2863.
〔13〕Mendenhall N P，et al．Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer〔J〕．Int J Radiat Oncol Biol Phys，2014，88（3）：596-602.
〔14〕Maude S L，et al．Chimeric antigen receptor T cells for sustained remissions in leukemia〔J〕．N Engl J Med，2014，371（16）：1507-1517.
〔15〕Lin Y，et al．Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers〔J〕．Proc Natl Acad Sci U S A，2014，111（42）：E4504-4512.
〔16〕Herbst R S，et al．Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients〔J〕．Nature，2014，515（7528）：563-567.
〔17〕Gubin M M，et al．Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens〔J〕．Nature，2014，515（7528）：577-581.
〔18〕Gragert L，et al．HLA match likelihoods for hematopoietic stem-cell grafts in the U．S．registry〔J〕．N Engl J Med，2014，371（4）：339-348.
〔19〕Brastianos K，et al．Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas〔J〕．Nat Genet，2014，46（2）：161-165.
〔20〕Bonadies D C，et al．Adverse events in cancer genetic testing：the third case series〔J〕．Cancer J，2014，20（4）：246-53.
〔21〕Retraction notice to「Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize」Food Chem Toxicol，2014，63：244.
〔22〕Wolchok J D，et al．Nivolumab plus ipilimumab in advanced melanoma〔J〕．N Engl J Med，2013，369（2）：122-133.
〔23〕Watson I R，et al．Emerging patterns of somatic mutations in cancer〔J〕．Nat Rev Genet，2013，14（10）：703-718.
〔24〕Vacchelli E，et al．Trial watch：Oncolytic viruses for cancer therapy〔J〕．Oncoimmunology，2013，2（6）：e24612.
〔25〕Shi Y，et al．Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer （ICOGEN）：a randomised，double-blind phase 3 non-inferiority trial〔J〕．Lancet Oncol，2013，14（10）：953-961.
〔26〕Nixon I J，et al．The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer，based on Memorial Sloan-Kettering Cancer Center risk group stratification〔J〕．Thyroid，2013，23（6）：683-694.
〔27〕Li Y，et al．Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer〔J〕．PLoS One，2013，8（1）：e52093.
〔28〕Lawrence M S，et al．Mutational heterogeneity in cancer and the search for new cancer-associated genes〔J〕．Nature，2013，499（7457）：214-218.
〔29〕Hamid O，et al．Safety and tumor responses with lambrolizumab （anti-PD-1） in melanoma〔J〕．N Engl J Med，2013，369（2）：134-144.
〔30〕Chung C S，et al．Incidence of second malignancies among patients treated with proton versus photon radiation〔J〕．Int J Radiat Oncol Biol Phys，2013，87（1）：46-52.
〔31〕Arcila M E，et al．EGFR exon 20 insertion mutations in lung adenocarcinomas：prevalence，molecular heterogeneity，and clinicopathologic characteristics〔J〕．Mol Cancer Ther，2013，12（2）：220-229.
〔32〕Wang Y C，et al．Comparison of Cancer Incidence between China and the USA〔J〕．Cancer Biol Med，2012，9（2）：128-132.
〔33〕Topalian S L，et al．Safety，activity，and immune correlates of anti-PD-1 antibody in cancer〔J〕．N Engl J Med，2012，366（26）：2443-2454.
〔34〕Seralini G E，et al．Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize〔J〕．Food Chem Toxicol，2012，50（11）：4221-4231.
〔35〕Lim S S，et al．A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions，1990-2010：a systematic analysis for the Global Burden of Disease Study 2010〔J〕．Lancet，2012，380（9859）：2224-2260.
〔36〕Govindan R，et al．Genomic landscape of non-small cell lung cancer in smokers and never-smokers〔J〕．Cell，2012，150（6）：1121-1134.
〔37〕An S J，et al．Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status〔J〕．PLoS One，2012，7（6）：e40109.
〔38〕Zava T T，Zava D T．Assessment of Japanese iodine intake based on seaweed consumption in Japan：A literature-based analysis〔J〕．Thyroid Res，2011，4：14.
〔39〕Wagle N，et al．Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling〔J〕．J Clin Oncol，2011，29（22）：3085-3096.
〔40〕Sequist L V，et al．Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors〔J〕．Sci Transl Med，2011，3（75）：75ra26.
〔41〕Ramaekers B L，et al．Systematic review and meta-analysis of radiotherapy in various head and neck cancers：comparing photons，carbon-ions and protons〔J〕．Cancer Treat Rev，2011，37（3）：185-201.
〔42〕Pederson T，Mukherjee S．The Emperor of All Maladies A Biography of Cancer〔J〕．Science，2011，332（6028）：423-423.
〔43〕Moeller B J，et al．Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy〔J〕．Radiat Oncol，2011，6：58.
〔44〕Miller L H，Su X．Artemisinin：discovery from the Chinese herbal garden〔J〕．Cell，2011，146（6）：855-858.
〔45〕Kantoff W，et al．Sipuleucel-T immunotherapy for castration-resistant prostate cancer〔J〕．N Engl J Med，2010，363（5）：411-422.
〔46〕Domchek S M，et al．Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality〔J〕．JAMA，2010，304（9）：967-975.
〔47〕Sawka A M，et al．Second primary malignancy risk after radioactive iodine treatment for thyroid cancer：a systematic review and meta-analysis〔J〕．Thyroid，2009，19（5）：451-457.
〔48〕Little M P．Cancer and non-cancer effects in Japanese atomic bomb survivors〔J〕．J Radiol Prot，2009，29（2A）：A43-59.
〔49〕Lawenda B D，et al．Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy？〔J〕．J Natl Cancer Inst，2008，100（11）：773-783.
〔50〕Dishop M K，Kuruvilla S．Primary and metastatic lung tumors in the pediatric population：a review and 25-year experience at a large children's hospital〔J〕．Arch Pathol Lab Med，2008，132（7）：1079-1103.
〔51〕Ballen K K，et al．Collection and preservation of cord blood for personal use〔J〕．Biol Blood Marrow Transplant，2008，14（3）：356-363.
〔52〕Schoder H，Gonen M．Screening for cancer with PET and PET/CT：potential and limitations〔J〕．J Nucl Med，2007，48 Suppl 1：4S-18S.
〔53〕McLaughlin J R，et al．Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations：a case-control study〔J〕．Lancet Oncol，2007，8（1）：26-34.
〔54〕Kelly E，Russell S J．History of oncolytic viruses：genesis to genetic engineering〔J〕．Mol Ther，2007，15（4）：651-659.
〔55〕Eapen M，et al．Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia：a comparison study〔J〕．Lancet，2007，369（9577）：1947-1954.
〔56〕Bjelakovic G，et al．Mortality in randomized trials of antioxidant supplements for primary and secondary prevention：systematic review and meta-analysis〔J〕．JAMA，2007，297（8）：842-857.
〔57〕Pearse A M，Swift K．Allograft theory：transmission of devil facial-tumour disease〔J〕．Nature，2006，439（7076）：549.
〔58〕Murgia C，et al．Clonal origin and evolution of a transmissible cancer〔J〕．Cell，2006，126（3）：477-487.
〔59〕Garber K．China approves world's first oncolytic virus therapy for cancer treatment〔J〕．J Natl Cancer Inst，2006，98（5）：298-300.
〔60〕Druker B J，et al．Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia〔J〕．N Engl J Med，2006，355（23）：2408-2417.
〔61〕Lundkvist J，et al．Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma〔J〕．Cancer，2005，103（4）：793-801.
〔62〕Ludwig J A，Weinstein J N．Biomarkers in cancer staging，prognosis and treatment selection〔J〕．Nat Rev Cancer，2005，5（11）：845-856.
〔63〕van der Zee，J．Heating the patient：a promising approach？〔J〕．Ann Oncol，2002，13（8）：1173-1184.
〔64〕Srivastava S R．Gopal-Srivastava，Biomarkers in cancer screening：a public health perspective〔J〕．J Nutr，2002，132（8 Suppl）：2471S-2475S.
〔65〕Miralbell R，et al．Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors〔J〕．Int J Radiat Oncol Biol Phys，2002，54（3）：824-829.
〔66〕Nishimura H，et al．Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor〔J〕．Immunity，1999，11（2）：141-151.
〔67〕Patterson R E，et al．Vitamin supplements and cancer risk：the epidemiologic evidence〔J〕．Cancer Causes Control，1997，8（5）：786-802.
〔68〕Jha P，et al．The antioxidant vitamins and cardiovascular disease．A critical review of epidemiologic and clinical trial data〔J〕．Ann Intern Med，1995，123（11）：860-872.
〔69〕Ferrara J L，Abhyankar S，Gilliland D G.Cytokine storm of graft-versus-host disease：a critical effector role for interleukin-1〔J〕．Transplant Proc，1993，25（1 Pt 2）：1216-1217.
〔70〕Newcomb P A，Carbone P P．The health consequences of smoking．Cance〔J〕r．Med Clin North Am，1992，76（2）：305-331.
〔71〕Martuza R L，et al．Experimental therapy of human glioma by means of a genetically engineered virus mutant〔J〕．Science，1991，252（5007）：854-856.
〔72〕Rosenberg S A，et al．Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer〔J〕．N Engl J Med，1985，313（23）：1485-1492.
〔73〕Morahan P S，et al．Paradoxical effects of immunopotentiators on tumors and tumor viruses〔J〕．J Infect Dis，1976，133 Suppl：A249-255.
〔74〕Yohn D S，et al.Oncolytic potentials of nonhuman viruses for human cancer．Ⅱ．Effects of five viruses on heterotransplantable human tumors〔J〕．J Natl Cancer Inst，1968，41（2）：523-529.
〔75〕Moore A E．Effects of viruses on tumors〔J〕．Annu Rev Microbiol，1954，8：393-410.
〔76〕Southam C M，Moore A E．Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus〔J〕．Cancer，1952，5（5）：1025-1034.
〔77〕CBSnews .Killing Cancer〔OL〕．http://www.cbsnews.com/news/polio-cancer-treatment-duke-university-60-minutes-scott-pelley/2015，3.29.
〔78〕https://clinicaltrials.gov/ct2/show/NCT0149189
〔79〕Li Z，et.al，Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells〔J〕．Cancer Cell．2009，2；15（6）：501-513.
〔80〕Gromeier M．et.al，Oncolytic polio virotherapy of cancer.Cancer〔J〕．2014，120（21）：3277-3286.